Peer Review History

Original SubmissionAugust 28, 2024
Decision Letter - Omid Dadras, Editor

PONE-D-24-33957A randomized trial to evaluate a complex, co-created, culture-sensitive intervention to promote healthy lifestyles and compliance to therapy in immigrants with type 2 diabetes: a protocol of a multicenter Italian studyPLOS ONE

Dear Dr. Venturelli,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 22 2024 11:59PM, If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Omid Dadras, MD, PhD

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

3. One of the noted authors is a group or consortium [DIABETHIC Working group]. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.

4. We note that the original protocol that you have uploaded as a Supporting Information file contains an institutional logo. As this logo is likely copyrighted, we ask that you please remove it from this file and upload an updated version upon resubmission.

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This study protocol addresses a significant health issue (uncontrolled diabetes in immigrants) using a culturally sensitive and participatory intervention approach for a multi-center clinical trial. The protocol has an explanatory introduction, reviewing relevant literature, and a thorough well-detailed methodology with clear outcome measures. In addition, the protocol is registered and adheres to ethical guidelines, with required checklists provided as supplementary files.

In the discussion part, the authors acknowledge that strict replication and generalization of the study results in other settings and centers may be difficult due to the complexity of the intervention, the need for local adaptations, and differences in usual care.

However, there are areas where the manuscript could be improved:

1- The S3 Appendix Figure (Results of barriers’ analysis by center) is neither explained nor mentioned in the manuscript text and should be referenced and explained for clarity.

2- While the current discussion part deals with the limitations of prior interventions, I recommend the authors explore more in-depth the comparison between this protocol and specific past studies, which would enhance the clarity and strength of the argument. Briefly referencing key studies and clearly highlighting how their co-creation approach differs from previous studies with comparable methods, as well as its potential impact on diabetes management efficacy.

3- The study states that the intervention will not be blinded to participants or investigators, which increases the risk of performance bias, particularly when behavioral interventions are being evaluated. It would be beneficial to talk more about ways to lessen this bias.

Reviewer #2: Authors plan to conduct a multicentre randomized controlled trial (RCT) to assess the effectiveness of a co-created health promotion intervention for immigrants with T2D. They will recruit 200 participants from four centers randomized into two arms: health promotion practice and experimental health promotion intervention. The focus will be on diet, physical activity, and therapeutic adherence.

1. Table 1 is unclear to this reviewer. Some more explanations for table 1 are needed.

2. Data will be collected from four centers and it seems that the intervention will not be identical. If so, how to address the potential heterogeneity?

3. Line 263. Typo: enrolls not enrols

4. Why won’t the statistician be blinded to group assignments? is there any reason to be unblinded?

5. What questionnaire will be used for interview?

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 1

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

RE: ok, done

2. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

RE: the article presents a study protocol. There are no data available.

3. One of the noted authors is a group or consortium [DIABETHIC Working group]. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.

RE: Ok, we have done it

4. We note that the original protocol that you have uploaded as a Supporting Information file contains an institutional logo. As this logo is likely copyrighted, we ask that you please remove it from this file and upload an updated version upon resubmission.

RE: we removed the logo from the document

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

RE: we’ve checked the references

Reviewers' comments:

Reviewer #1: This study protocol addresses a significant health issue (uncontrolled diabetes in immigrants) using a culturally sensitive and participatory intervention approach for a multi-center clinical trial. The protocol has an explanatory introduction, reviewing relevant literature, and a thorough well-detailed methodology with clear outcome measures. In addition, the protocol is registered and adheres to ethical guidelines, with required checklists provided as supplementary files.

In the discussion part, the authors acknowledge that strict replication and generalization of the study results in other settings and centers may be difficult due to the complexity of the intervention, the need for local adaptations, and differences in usual care.

RE: thank you for the comment and the careful revision

However, there are areas where the manuscript could be improved:

1- The S3 Appendix Figure (Results of barriers’ analysis by center) is neither explained nor mentioned in the manuscript text and should be referenced and explained for clarity.

RE: Thank you for the comment. We got confused with the citations of the supplementary materials. Now, we correctly number supplementary files. S2 Appendix Figure is the result of the local analysis reported in lines 221-223 (page 9).

2- While the current discussion part deals with the limitations of prior interventions, I recommend the authors explore more in-depth the comparison between this protocol and specific past studies, which would enhance the clarity and strength of the argument. Briefly referencing key studies and clearly highlighting how their co-creation approach differs from previous studies with comparable methods, as well as its potential impact on diabetes management efficacy.

RE: thank you for the comment. We expanded the discussion on the dissimilarities in the co-creation approach of our study compared to previous studies. The main differences were related to stakeholders, phases of the research process involved, and methods. (see lines 364-383, page 17).

3- The study states that the intervention will not be blinded to participants or investigators, which increases the risk of performance bias, particularly when behavioral interventions are being evaluated. It would be beneficial to talk more about ways to lessen this bias.

RE: We agree with the reviewer that the lack of blinding of participants or investigators increases the risk of performance bias. Unfortunately, the blinding was not intrinsically feasible in our trial. To lessen the bias we decided to use an objective outcome as primary outcome of our study (i.e. change of HbA1c 12 months after recruitment), and to involve experienced health professionals for the performance of the interventions, specifically sensitize and trained on good practices for the conduction of research studies. Indeed, we will take into account the potential implication of performance bias during the interpretation of our findings, including qualitative information arising from the co-evaluation phase of our study. We added a sentence in the manuscript to include details on this crucial point. We thank the reviewer for this comment. (see lines 275-281 page 13).

Reviewer #2: Authors plan to conduct a multicentre randomized controlled trial (RCT) to assess the effectiveness of a co-created health promotion intervention for immigrants with T2D. They will recruit 200 participants from four centers randomized into two arms: health promotion practice and experimental health promotion intervention. The focus will be on diet, physical activity, and therapeutic adherence.

1. Table 1 is unclear to this reviewer. Some more explanations for table 1 are needed.

RE: Ok, we tried to explain the table a little better. Lines 136-143 (page 5-6).

2. Data will be collected from four centers and it seems that the intervention will not be identical. If so, how to address the potential heterogeneity?

RE: We thank the reviewer for this comment. This is a crucial methodological issue when assessing co-created and context-adapted complex interventions in multicentre trials.

As presented in section 1.1.3 and Table 1, we decided to combine the standardization of the intervention by function (rather than by form) suggested by the Medical Research Council (Skivington K et al 2021) for the evaluation of complex interventions, with a careful conceptualization of what was the object of the evaluation (i.e. the contrast vs. the usual care defined by similar incremental effort). This led us to build an experimental design that could compare the novelty of the intervention in contrast to the existing usual care in centers with different backgrounds. Thus, the heterogeneity we should take into account will be the one emerging at function and incremental effort levels, which will be probably lower than the heterogeneity we would have taken into account considering the differences in the form of the intervention’s components. Despite this, whether the heterogeneity at function and incremental effort level will be high, proper analysis will be used to take it into account. We added a sentence on this point in the discussion section. (lines 354-356, page 16-17)

3. Line 263. Typo: enrolls not enrols

RE: we correct it.

4. Why won’t the statistician be blinded to group assignments? is there any reason to be unblinded?

RE: We thank the reviewer for this comment. Although the variable on the randomization arm can be masked, we consider it appropriate to consider the statistician unblinded because there are variables in the database describing the health promotion intervention that clearly differs between arms. These variables cannot be masked because they are among those to be included in the analysis.

5. What questionnaire will be used for interview?

RE: Whether the comment was referred to the questionnaires used to assess dietary habits and physical activity, we used the Mediterranean Diet Score, (MedDietScore) and the International Physical Activity Questionnaire - Short Form, IPAQ-SF, as reported in 2.1.9 paragraph on data collection.

Whether the comment was related to the questions included in the interviews performed during the co-creation process, no standardized questionnaires were used. Open-ended questions related to barriers and solutions were prepared ad-hoc by the qualitative research team and shared with the principal investigators of each recruiting center to guide the co-creation process. We included a sentence in the manuscript to clarify this point. (lines 212-213)

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Omid Dadras, Editor

A randomized trial to evaluate a complex, co-created, culture-sensitive intervention to promote healthy lifestyles and compliance to therapy in immigrants with type 2 diabetes: a protocol of a multicenter Italian study

PONE-D-24-33957R1

Dear Dr. Francesco Venturelli

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Omid Dadras, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for your detailed responses to the comments and for making the necessary revisions. I appreciate the clarifications and the improvements made to the manuscript, particularly in the area of the discussion of potential biases. The adjustments have significantly enhanced the clarity of the manuscript.

No further revisions are required at this stage.

Reviewer #2: Thanks for taking your time to address the comments. All raised comments have been satisfactory addressed.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Omid Dadras, Editor

PONE-D-24-33957R1

PLOS ONE

Dear Dr. Venturelli,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Omid Dadras

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .